Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
We seem to have some activity recently - any one offer any insight as to why?
I'm still in, since the LPX days, but haven't been following the price since we left AIM. I assume the supertanker sank?
Lord, I would be interested to hear your thoughts also. If you wouldn't mind, please include: xeneticbio@hotmail.co.uk
Mathsprof, My broker is selftrade; they sent me this news yesterday after waiting since February for my share certificate! My account is now updated and showing my shares, although, I haven't tried to buy or sell yet.
SCHEME OF ARRANGEMENT "Xenetic Biosciences Inc Shares, we have now been able to transfer the new stock into CREST"
I received an email from my broker on the 14th of February explaining that they were sending off for my certificates; however, I have never received them. After many painful conversations with my broker they are still sticking with the same story, 'we're not sure how long it will take, all we know is that it can take months'. They cannot give me any more information of any other contact details. Do you know of any way to expedite this long and tedious wait? Thanks
Thank you both. This is going to be another long and painful conversation; similar to that I have had with them all week. I shall report back with the outcome.
Thank you, so why are they saying my entitlement is 585 shares and not 32,840?
My Lord, may you assist me in understanding the below corporate action. I hold 102,625 shares and they are saying that my entitlement is 585 shares? SCHEME OF ARRANGEMENT Your holding has now been converted at a rate of 1 New Xenetic Biosciences Inc Share for every 175 existing shares held and then each New Xenetic Bioscience Share has been sub-divided into 56 New Xenetic Biosciences Shares (ISIN:US9840151073). The resultant shares will be adjusted on your account shortly. As this stock is not CREST eligible we will be unable to hold it in our service and you will therefore receive a certificate registered in your own name in due course. If however you hold the security in a SIPP or CTF account then we are not permitted to transfer this into your own name and we will therefore hold this residually (outside of CREST) on your behalf. Please be aware that as the resulting holding will be in the form of a US share certificate there may be a significant delay in you receiving this from us. This is due to transfer regulations in North America which require additional verification and guarantees prior to the share certificate being issued to us. These delays are out of our control however please be assured that we will make every attempt to get your share certificate to you as soon as possible.
Does any one else use selftrade.co.uk?
06.06.12: The novel polysialyated Factor VIII candidate is now expected to enter Western clinical trials in H1-2013. 27.09.12: We remain confident that the polysialylated recombinant Factor VIII molecule licensed to Baxter Healthcare will, quite independent of the above, enter trials in Europe in spring 2013. 06.06.13: Baxter collaboration positive, additional US$1m license fee payable in June 2013 Following a decision by Baxter to move this program into their follow-on development program this candidate is now expected to enter Western clinical trials in 2014. Baxter has affirmed that PSA-Factor VIII is an important pipeline product intended to strengthen their Haemophilia-A portfolio. Accordingly, Baxter is due to pay a license extension fee of US$1m to the Group which falls due on 30th June 2013.
Many thanks, as always; I am hoping for good positive Q4 2013 and, hopefully, a return on my investment.
13/02/13: Xenetic Biosciences plc (LSE: XEN.L) announces that, in a Phase I/IIa IV (intra venous) clinical trial, its co-development partner, the Serum Institute of India ("SIIL"), has dosed its first patient with their jointly-owned ErepoXen® candidate. The 6-month trial will encompass 40 Chronic Renal Failure patients on dialysis and the end points will be to confirm safety and reductions in the frequency of dosage. 02/09/13: SIIL has confirmed they have started screening patients for this Phase I/II study at five sites in India. Starting this month, patients have been screened and three passed for active treatment in a trial which aims to recruit a total of 40 patients. Does this mean that only three people have been screened since the 13/02/13? How long does it take to screen and then receive the results; additionally, do you know if this is this also a '6 month trial'? Thanks in advance.
From the latest conference call I was lead to believe that the start of the Western clinical trials, in Australia, for ErepoXen was imminent; therefore, starting in June or, by the latest, July. However, August is nearly here and no news. Proactive investors have now suggested it may be August http://www.proactiveinvestors.co.uk/companies/news/59101/xenetic-biosciences-expects-higher-rating-from-us-switch-59101.html. Come on Scott.
My favourite comment of the whole conference call... supertanker downsized to a battleship. I have even underlined it on my notes.
Many thanks for your reply. However, do you think the market will perceive the Australian PSA-EPO Ph II trails and give them as much 'respect' as what you do? Additionally, has Scott given a time scale to the out licensing? I just keep focusing on trial results to be honest. Thanks
Do you expect to hear Phase I/IIa IV results for ErepoXen before the end of H1, after all, the 6th month trial started nearly 16 months ago? How about any news on the large Pharma company mentioned around the same time? Thanks
Wincanton have been talking about there 7 new sectors. Anyone know what these are? thanks